


Prepaire Labs Enters Negotiations with European Investment Firm in \$30 Million Deal

DUBAI, UNITED ARAB EMIRATES, May 23, 2023 /EINPresswire.com/ --Prepaire Labs, a pioneering <u>biotechnology</u> company revolutionizing <u>drug discovery</u> and precision medicine, has entered into advanced negotiations with a European investment firm regarding a significant equity stake. The proposed deal, valued at \$30 million USD, marks a significant milestone in Prepaire Labs' growth trajectory and reinforces its position in the healthcare innovation space.



The undisclosed investment firm is recognized for its strategic investments in early stage cuttingedge companies, has expressed a strong interest in Prepaire Labs' innovative technologies, predictive models, and their potential to transform the field of drug discovery. Through this proposed investment, Prepaire Labs aims to further accelerate its research and development efforts, expand its operations, and enhance its commercialization capabilities of the Prepaire Operating System HAiLO[™].

The \$30 million investment represents a substantial commitment from the investment firm, underscoring their confidence in Prepaire Labs' vision, capabilities, and potential for market disruption. The negotiations are centered around establishing a mutually beneficial partnership that will not only provide Prepaire Labs with the necessary capital to fuel its growth but also leverage the investment firm's industry expertise, network, and resources.

"We are excited to be in advanced negotiations with the investment firm for this significant transaction," said Dr Vicent Ribas, Co-Founder and Chief Scientific Officer of Prepaire Labs. "Their recognition of our innovative technologies and predictive models validates our commitment to revolutionizing healthcare. This investment will not only provide us with the necessary financial resources but also offer strategic support to drive our mission forward and deliver impactful solutions to patients and the broader healthcare ecosystem."

The investment firm's representative expressed enthusiasm for the potential partnership, stating, "Prepaire Labs places a strong emphasis on biology at scale. Their data pipelines and automation infrastructure enable the generation of massive amounts of high-quality data, surpassing traditional artisanal approaches. This extensive scale allows Prepaire Labs to explore a broader range of human disease diversity and potential therapies."

He continued, "Prepaire Labs has demonstrated remarkable innovation and a unique approach to transforming drug discovery and precision medicine. We are impressed by their achievements and confident in their ability to make a substantial impact in the healthcare industry. Through this investment, we aim to provide Prepaire Labs with the necessary resources and strategic guidance to drive their growth and help them achieve their ambitious goals."

The negotiations for the sale of the stake in Prepaire Labs are expected to conclude in the coming weeks, subject to customary closing conditions. Upon successful completion, the investment will fortify Prepaire Labs' position as a contender in the healthcare technology sector and propel its mission of revolutionizing patient care and drug discovery.

About Prepaire Labs:

Prepaire Labs is a pioneering healthcare technology company focused on revolutionizing drug discovery and precision medicine. Through the integration of deep learning and biology, Prepaire Labs develops predictive models, innovative technologies, and data-driven solutions to drive advancements in healthcare and improve patient outcomes.

By leveraging population-scale data, Prepaire Labs constructs predictive models grounded in human genetic, phenotypic, and clinical data. These models provide insights into the underlying architecture and biology of diseases, facilitating the development of more accurate predictive models. Additionally, Prepaire Labs utilizes patient-derived induced pluripotent stem cells (iPSCs), genome editing, high-content cellular phenotyping, and machine learning to create in vitro disease models that optimize genetics, cell-type, environment, and multidimensional data collection for increased predictability of human clinical outcomes.

Prepaire Labs' innovative approach holds the potential to revolutionize the field of drug discovery, enabling the development of new medicines and improving patient outcomes.

Visit us at International Precision Med Summit, Dubai May 23/24 2023 Booth C17

Vanesa Valkova Prepaire Labs media@prepaire.com Visit us on social media: Twitter This press release can be viewed online at: https://www.einpresswire.com/article/635238032

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.